Cheng Liu - 25 Aug 2026 Form 4 Insider Report for Estrella Immunopharma, Inc. (ESLA)

Reporting relationship: CEO, Director
Issuer ticker: ESLA
Reported as of: 25 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Aug 2026, 19:23:37 UTC
Prior SEC filing: 14 Feb 2025
Source filing: View source filing
Reporting owner signature: Vivien Chan

Key filing fact

Cheng Liu filed Form 4 for Estrella Immunopharma, Inc. (ESLA) on 26 Aug 2026.

Key facts

This page summarizes Cheng Liu's Form 4 filing for Estrella Immunopharma, Inc. (ESLA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 26 Aug 2026, 19:23.

Change

Previous filing in this sequence was filed on 14 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001996255 Primary reporting owner

Liu Cheng

Relationship: CEO, Director
Address: C/O ESTRELLA IMMUNOPHARMA, INC., 5858 HORTON STREET, SUITE 370, EMERYVILLE
Signature: Vivien Chan
Signature date: 26 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ESLA transaction

Common Stock, par value $0.0001 per share

Options Exercise

Transaction value
Shares: +100,000
Change %: +34%
Price: $0.8150^*
Shares after: 397,437
Date: 25 Aug 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ESLA transaction Derivative

Incentive Stock Option

Options Exercise

Transaction value
Shares: +100,000
Change %: +12%
Price: $0.000000^*
Shares after: 900,000
Date: 25 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $0.8150
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Represents the exercise price per share paid by the Reporting Person upon the exercise of the stock options reported in Table II.

Footnote F2

Reflects the 297,437 shares of Common Stock directly beneficially owned as reported on the Reporting Person's most recent Form 4, plus the 100,000 shares acquired upon the reported exercise.

Footnote F3

Represents incentive share options granted to the Reporting Person on October 30, 2024 under the Issuer's 2023 Omnibus Incentive Plan, of which twenty-five percent (25%) was immediately exercisable on the date of grant, with the remainder vesting in equal monthly installments of 1/48th of the total award on each monthly anniversary of October 30, 2024. The options were vested as to the shares exercised.

Footnote F4

Not applicable. The reported transaction is the exercise of the stock option for the exercise price set forth in Column 2. No separate consideration was paid or received for the derivative security.